1. Home
  2. AMRX vs KNSA Comparison

AMRX vs KNSA Comparison

Compare AMRX & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amneal Pharmaceuticals Inc.

AMRX

Amneal Pharmaceuticals Inc.

HOLD

Current Price

$18.05

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Logo Kiniksa Pharmaceuticals Ltd.

KNSA

Kiniksa Pharmaceuticals Ltd.

HOLD

Current Price

$63.61

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMRX
KNSA
Founded
2002
2015
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
4.9B
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
AMRX
KNSA
Price
$18.05
$63.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
7
Target Price
$15.60
$60.86
AVG Volume (30 Days)
2.1M
996.3K
Earning Date
05-01-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
157.89
225.00
EPS
0.19
0.27
Revenue
N/A
$677,564,000.00
Revenue This Year
$4.48
$37.48
Revenue Next Year
$7.13
$17.87
P/E Ratio
$92.18
$232.74
Revenue Growth
N/A
60.09
52 Week Low
$7.67
$26.27
52 Week High
$18.39
$67.53

Technical Indicators

Market Signals
Indicator
AMRX
KNSA
Relative Strength Index (RSI) 67.85 58.22
Support Level $12.46 $37.62
Resistance Level N/A $67.53
Average True Range (ATR) 0.59 2.72
MACD -0.05 -0.39
Stochastic Oscillator 80.15 46.82

Price Performance

Historical Comparison
AMRX
KNSA

About AMRX Amneal Pharmaceuticals Inc.

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Share on Social Networks: